The Global Fund to Fight AIDS, Tuberculosis, and Malaria has announced a five-year, ¥1 billion ($9 million) pledge from Takeda Pharmaceutical in support of efforts to improve maternal and child health in Africa.
Building on a previous ten-year, ¥1 billion commitment from the company, the gift will support the integration of quality HIV, tuberculosis, and malaria services with prenatal and postnatal care in several countries. The earlier gift from the company was used to strengthen malaria prevention efforts in Tanzania, improve access to TB treatment in Kenya, and expand HIV services and awareness of the virus in Nigeria.
"We are deeply inspired by the Takeda initiative's impact on strengthening healthcare workforce capacity in Kenya, Nigeria, and Tanzania to prevent and address the world's three biggest infectious disease killers," said Takeda president and CEO Christophe Weber. "Our commitment to better health and a brighter future extends beyond our work at the cutting edge of innovation to bold, long-term investments in disease prevention, capacity building, and access to health care in partnership with the global community."